The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
With the paradigm shift created by psychedelics, a recent study suggests reconsidering the medical model of mental illness.
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
Researchers are uncovering reasons to think there’s more to DMT than just hallucinations.
“In the pharmaceutical drug development community, this is what you dream about.”
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.